Literature DB >> 12798953

Interactions of gamma-hydroxy butyrate with ethanol and NCS 382.

Richard J Lamb1, Jaclyn Munn, Nicklaus J Duiker, Andrew Coop, Huifang Wu, Wouter Koek, Charles P France.   

Abstract

We examined the effects of gamma-hydroxy butyrate (GHB) alone and in combination with either ethanol or NCS 382 [(2E)-(5-hydroxy-5,7,8,9-tetrahydro-6H-benzo[a][7]annulen-6-ylidene], a purported antagonist at the GHB receptor. These effects were examined on the responding of rats under a fixed-ratio (FR) 10 schedule of sugar solution (14%, w/v; 0.1 ml) presentation. GHB dose-relatedly decreased responding. When GHB was combined with ethanol, the effects of the two drugs were less than additive. NCS 382 did not antagonize the rate-decreasing effects of GHB. These observations are consistent with the notion that many of the behavioral actions of exogenously administered GHB result from GHB's actions at sites other than the GHB receptor, and are inconsistent with the popular notion that the effects of GHB and ethanol are synergistic.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12798953     DOI: 10.1016/s0014-2999(03)01791-6

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  3 in total

1.  Involvement of gamma-hydroxybutyrate (GHB) and GABA-B receptors in the acute behavioral effects of GHB in baboons.

Authors:  Amy K Goodwin; Wolfgang Froestl; Elise M Weerts
Journal:  Psychopharmacology (Berl)       Date:  2005-03-01       Impact factor: 4.530

2.  Neuroleptic-like effects of gamma-hydroxybutyrate: interactions with haloperidol and dizocilpine.

Authors:  Rajkumar J Sevak; Charles P France; Wouter Koek
Journal:  Eur J Pharmacol       Date:  2004-01-12       Impact factor: 4.432

3.  Cognitive, psychomotor, and subjective effects of sodium oxybate and triazolam in healthy volunteers.

Authors:  Lawrence P Carter; Roland R Griffiths; Miriam Z Mintzer
Journal:  Psychopharmacology (Berl)       Date:  2009-06-20       Impact factor: 4.530

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.